NP-011 / Nexel - LARVOL DELTA

A Promising Novel Therapeutic Strategy for Inflammatory Bowel Disease Through Enhanced Efferocytosis and Anti-Inflammatory Mechanisms (ACG 2023) - "NP-011 demonstrated strong affinity to phosphatidylserine (PS) and boosted the uptake of PS and apoptotic cells (ACs) by macrophages, leading to an enhanced expression of HO-1. The maximum count of TUNEL-positive cells in mouse colons was observed on day five post-exposure to DSS. By strategically administering NP-011 on this pivotal day, we managed to effectively reduce the count of ACs, and lower the concentration of inflammation and necrosis markers in the blood."

Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

A Study of NP-011 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Completed | Sponsor: Nexel Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Myocardial Infarction

A Study of NP-011 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Active, not recruiting | Sponsor: Nexel Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2023 ➔ May 2023 | Trial primary completion date: Nov 2022 ➔ Mar 2023

Enrollment closed • Trial completion date • Trial primary completion date • Cardiovascular • Myocardial Infarction

A Study of NP-011 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=64 | Recruiting | Sponsor: Nexel Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Myocardial Infarction

NEXEL (BIO 2022) - "Our protein/Peptide therapy pipelines, NP-011 and NPT-0025, were designed by remodeling a protein found in embryonic stem cell secretomes. NEXEL is a specialist in the differentiation of human iPSC, having successfully developed several off-the-shelf products such as cardiomyocytes, hepatocytes, and neurons. hiPSC-derived cells are proving to be an excellent in vitro model to potentially revolutionize preclinical drug toxicity testing, as evidenced by upcoming ICH guideline changes(S7B) with CiPA."

Fibrosis • Hepatology • Immunology • Non-alcoholic Steatohepatitis